First-in-man clinical trial for Hunter syndrome underway

June 3, 2015, Emory University
First-in-man clinical trial for Hunter syndrome underway at Emory
Chris Dutcher, who was diagnosed with Hunter syndrome when he was six years old, is the first to test a newly developed drug for the rare genetic disorder.

A first-in-man clinical trial, testing a newly developed drug for a rare genetic condition called mucopolysaccharidosis type II (MPS II) or Hunter syndrome, is underway at Emory University.

MPS II or Hunter syndrome is an inherited disease in which long chains of sugar molecules, known as mucopolysaccharides, are not broken down correctly in the body. A deficiency in the enzyme iduronate-2-sulfatase (I2S) causes the problem. Without enough I2S, partially broken-down mucopolysaccharides accumulate in the organs and tissues of the body and become toxic.

An enzyme replacement medication called idursulfase or Elaprase (brand name) has commonly been used to treat Hunter syndrome, but it does not cross into the brain to treat the most severe cases of Hunter. Now, Emory researchers are testing idursulfase fused with an antibody developed by ArmaGen, Inc., to create a new method of delivery that will include the brain. This is the first time this medication combination, called AGT-182, has been tested in a human.

"We are using a technique where the has been attached to an antibody to the human insulin receptor, in an effort to move across the blood-brain barrier and be able to treat the brain," says William Wilcox, MD, PhD, professor in the Department of Human Genetics, Emory University School of Medicine and principal investigator of this clinical trial. "If this works, this is a brave new world that we're entering into in genetics where we can treat many diseases that involve the brain that we could never treat before."

Chris Dutcher and study principal investigator Dr. William Wilcox talk about Hunter Syndrome and this Phase I clinical trial.

Chris Dutcher was diagnosed with Hunter syndrome when he was six years old. He is now 31. Dutcher's symptoms include significant bone disease, short stature, stiff joints, an enlarged liver and spleen and difficulty breathing.

"By testing this new medication for the first time in a human, my hope is to help children with severe Hunter syndrome," says Dutcher, whose younger brother also has the same disorder.

Dutcher has the mild version of Hunter syndrome, but the symptoms are still quite serious and can involve the lining of the brain and spinal cord that are not treated by Elaprase, but may be treated AGT-182. The severe form is diagnosed in a child's first few years of life and can lead to progressive and profound intellectual disability and eventually death.

In this multicenter Phase I safety and efficacy trial, the study medication will be administered intravenously once a week for eight weeks.

Researchers have previously found that if given early enough, enzyme replacement therapy alone can delay or prevent some of the symptoms of Hunter syndrome. However, benefits in cognitive function have not been seen with intravenous enzyme replacement therapy.

Boys are affected by the disease, which is usually passed on by mothers who carry the gene.

"With an X-linked condition such as Hunter syndrome, the mom is usually a carrier," says Stephanie Cagle, genetic counselor and study coordinator at Emory. "Then with every pregnancy, if she's having a boy, there's a 50 percent chance that her child will inherit the carrier gene and develop Hunter syndrome."

There is no cure for Hunter syndrome, a brought on by a deficiency in a single enzyme in the cells. The syndrome affects one in about 100,000 males.

Explore further: Study holds hope of a treatment for deadly genetic disease, MPS IIIB

Related Stories

Study holds hope of a treatment for deadly genetic disease, MPS IIIB

September 29, 2014
MPS IIIB is a devastating and currently untreatable disease that causes progressive damage to the brain, leading to profound intellectual disability, dementia and death—often before reaching adulthood.

Correction of cardiovascular symptoms of MPS I in animal model

September 30, 2014
REGENXBIO Inc. today announced that gene transfer mediated by REGENXBIO's NAV AAV8 vectors resulted in sustained serum α-L-iduronidase (IDUA) expression, as well as correction of systemic features of MPS I, or Hurler syndrome, ...

Researchers report on promising new therapy for devastating genetic disorder

February 12, 2014
A promising new therapy has – for the first time – reduced damage to the brain that can be caused by Sanfilippo B (MPS IIIB), a rare and devastating genetic disease, Los Angeles Biomedical Research Institute (LA BioMed) ...

Stem cells hold hope for Hurler's syndrome

November 6, 2013
University of Adelaide research using special adult stem cells is promising new hope for better treatments for the devastating genetic disease Hurler's syndrome.

New cause of child brain tumor condition identified

December 2, 2014
Gorlin syndrome causes an increased risk of developing cancers of the skin and, rarely, in the brain. Around 1 in 30,000 people has the condition.

Cause of regression in individuals with Down syndrome identified

May 12, 2015
Down syndrome, the most common chromosomal disorder in America, can be complicated by significant deterioration in movement, speech and functioning in some adolescents and young adults. Physicians previously attributed this ...

Recommended for you

Exercise-induced hormone irisin triggers bone remodeling in mice

December 13, 2018
Exercise has been touted to build bone mass, but exactly how it actually accomplishes this is a matter of debate. Now, researchers show that an exercise-induced hormone activates cells that are critical for bone remodeling ...

Law professor suggests a way to validate and integrate deep learning medical systems

December 13, 2018
University of Michigan professor W. Nicholson Price, who also has affiliations with Harvard Law School and the University of Copenhagen Faculty of Law, suggests in a Focus piece published in Science Translational Medicine, ...

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Pain: Perception and motor impulses arise in brain independently of one another

December 13, 2018
Pain is a negative sensation that we want to get rid of as soon as possible. In order to protect our bodies, we react by withdrawing the hand from heat, for example. This action is usually understood as the consequence of ...

Researchers give new insight to muscular dystrophy patients

December 13, 2018
New research by University of Minnesota scientists has revealed the three-dimensional structure of the DUX4 protein, which is responsible for the disease, facioscapulohumeral muscular dystrophy (FSHD). Unlike the majority ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.